Saturn V Capital Management LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Saturn V Capital Management LP reported 23 stock positions worth $697.5 million. Its top holding was Amylyx Pharmaceuticals (AMLX) at 11.9% of the portfolio, followed by Alumis (ALMS, 11.8%) and Abivax SA-ADR (ABVX, 9.9%). Compared with Q1 2026, it opened 3 new positions, sold out of 1, added to 13 and reduced 6. The biggest buy was a new position in Trevi Therapeutics (TRVI) and the biggest sale an exit from Cogent Biosciences (COGT).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $697.5M (Q2 2026)
- SEC Filing
- 0001964437-26-000012 ↗ filed Aug 14, 2026
Holdings Value
Holdings 23 stocks · $697.5M
| AMLX Amylyx Pharmaceuticals Inc. | 11.91% | 4,624,101 | $83.0M | Add +6.3% |
| ALMS Alumis Inc. | 11.76% | 2,915,443 | $82.0M | Reduce -8.9% |
| ABVX Abivax SA-ADR | 9.91% | 518,865 | $69.1M | Reduce -4.4% |
| PCVX Vaxcyte Inc. | 7.11% | 852,914 | $49.6M | Add +3.4% |
| IMMX Immix Biopharma Inc. | 6.89% | 4,658,429 | $48.0M | Add +26.1% |
| PHVS Pharvaris NV | 6.52% | 1,314,122 | $45.4M | Add +9.4% |
| JAZZ Jazz Pharmaceuticals PLC | 5.56% | 160,938 | $38.8M | Reduce -1.2% |
| CELC Celcuity Inc. | 5.55% | 370,318 | $38.7M | Add +31.4% |
| IRON Disc Medicine Inc. | 5.50% | 524,730 | $38.4M | Add +16.6% |
| CADL Candel Therapeutics Inc. | 4.88% | 3,303,686 | $34.0M | Add +14.1% |
| XFOR X4 Pharmaceuticals Inc. | 4.67% | 6,973,343 | $32.6M | Add +8.0% |
| MNPR Monopar Therapeutics Inc. | 4.14% | 311,976 | $28.9M | Reduce -9.7% |
| DYN Dyne Therapeutics Inc. | 3.37% | 1,057,493 | $23.5M | Add +9.4% |
| TRVI Trevi Therapeutics Inc. | 2.81% | 1,052,043 | $19.6M | New |
| ZURA Zura Bio Ltd. | 1.78% | 2,101,119 | $12.4M | Add +183.9% |
| SGMT Sagimet Biosciences Inc. Class A | 1.64% | 1,479,918 | $11.4M | New |
| OCS Oculis Holding AG | 1.36% | 684,880 | $9.5M | Add +32.5% |
| IKT Inhibikase Therapeutics Inc. | 1.13% | 3,869,056 | $7.9M | Add +0.1% |
| VIR Vir Biotechnology Inc. | 1.13% | 770,643 | $7.9M | New |
| IVVD Invivyd Inc. | 1.05% | 8,392,288 | $7.3M | Reduce -23.4% |
| ANRO Alto Neuroscience Inc. | 0.69% | 182,829 | $4.8M | Add +105.4% |
| MSLE Satellos Bioscience Inc. | 0.39% | 350,000 | $2.7M | No change |
| OVID Ovid Therapeutics Inc. | 0.26% | 663,060 | $1.8M | Reduce -84.1% |
Portfolio Sells Q1 2026 → Q2 2026
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −4.37 |
| IVVD Invivyd Inc. | Reduce -23.4% | 1.05% | −1.53 |
| OVID Ovid Therapeutics Inc. | Reduce -84.1% | 0.26% | −1.42 |
| ABVX Abivax SA-ADR | Reduce -4.4% | 9.91% | −1.03 |
| ALMS Alumis Inc. | Reduce -8.9% | 11.76% | −1.01 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -1.2% | 5.56% | −0.02 |
| MNPR Monopar Therapeutics Inc. | Reduce -9.7% | 4.14% | +0.71 |
Portfolio Buys Q1 2026 → Q2 2026
| TRVI Trevi Therapeutics Inc. | New | 2.81% | +2.81 |
| CADL Candel Therapeutics Inc. | Add +14.1% | 4.88% | +2.31 |
| SGMT Sagimet Biosciences Inc. Class A | New | 1.64% | +1.64 |
| VIR Vir Biotechnology Inc. | New | 1.13% | +1.13 |
| ZURA Zura Bio Ltd. | Add +183.9% | 1.78% | +0.98 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +6.3% | 11.91% | +0.96 |
| IMMX Immix Biopharma Inc. | Add +26.1% | 6.89% | +0.79 |
| PHVS Pharvaris NV | Add +9.4% | 6.52% | +0.37 |
| ANRO Alto Neuroscience Inc. | Add +105.4% | 0.69% | +0.33 |
| IRON Disc Medicine Inc. | Add +16.6% | 5.50% | +0.29 |
| DYN Dyne Therapeutics Inc. | Add +9.4% | 3.37% | +0.19 |
| IKT Inhibikase Therapeutics Inc. | Add +0.1% | 1.13% | −0.05 |
| XFOR X4 Pharmaceuticals Inc. | Add +8.0% | 4.67% | −0.16 |
| CELC Celcuity Inc. | Add +31.4% | 5.55% | −0.27 |
| OCS Oculis Holding AG | Add +32.5% | 1.36% | −1.13 |
| PCVX Vaxcyte Inc. | Add +3.4% | 7.11% | −1.57 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |